In this study, we utilized the human neuroblastoma cell line SH-SY5Y to establish pharmacological models of Gaucher, NPA, and NPC diseases, enabling the evaluation of c-Abl/TFEB pathway activation and its impact on lysosomal clearance. Here, TFEB is linked to neuroblastoma.